Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis

Medicine
Lianjie LinChangqing Zheng

Abstract

We sought to evaluate the safety and efficacy of available biologics that inhibit T-cell migration by blocking α4β7 integrins in inflammatory bowel diseases. The aim of this study is to evaluate whether Crohn disease (CD) patients receiving either vedolizumab or natalizumab have any different effect in CD Activity Index (CDAI). Using Medline, Excerpta Medica dataBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar until October 31, 2013, we identified 10 studies examining the safety and efficacy of specific integrin inhibitors—vedolizumab, which targets an epitope comprising the α4β7 heterodimer; natalizumab, which recognizes the α4 integrin subunit; etrolizumab, which is specific for the β7 subunit—in the treatment of CD and ulcerative colitis (UC). CD patients receiving either vedolizumab or natalizumab demonstrated a modest increase in remission rate, when compared with that of the placebo group. Further, although both treatments reduced the CDAI slightly, the observed clinical response was less robust than that of the remission rate. UC patients treated with vedolizumab and natalizumab were found to show more prominent increases in both remission and clinical response, compared with placebo, th...Continue Reading

References

Jan 3, 2003·The New England Journal of Medicine·Subrata GhoshUNKNOWN Natalizumab Pan-European Study Group
Jan 3, 2003·The New England Journal of Medicine·Ulrich H von Andrian, Britta Engelhardt
Jun 17, 2005·The New England Journal of Medicine·Brian G FeaganMargaret K Vandervoort
Jul 29, 2005·Immunological Reviews·Marko Salmi, Sirpa Jalkanen
Jul 30, 2005·European Journal of Immunology·Britta Engelhardt, Michael J Briskin
Nov 4, 2005·The New England Journal of Medicine·William J SandbornUNKNOWN Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
May 9, 2007·Gastroenterology·Stephan R TarganUNKNOWN International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
May 15, 2007·Lancet·Daniel C Baumgart, William J Sandborn
Oct 3, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Brian G FeaganAsit Parikh
Nov 4, 2011·The New England Journal of Medicine·Silvio Danese, Claudio Fiocchi
May 18, 2012·The New England Journal of Medicine·Gary BloomgrenCarmen Bozic
Feb 12, 2013·Expert Opinion on Biological Therapy·Mahmoud H Mosli, Brian G Feagan
Apr 30, 2013·Current Drug Targets·Giorgos BamiasJesús Rivera-Nieves
Aug 24, 2013·The New England Journal of Medicine·Brian G FeaganUNKNOWN GEMINI 1 Study Group
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Nov 20, 2013·Digestive Diseases·Klaus Fellermann

❮ Previous
Next ❯

Citations

Jun 4, 2015·Current Opinion in Gastroenterology·Paula Sousa, Matthieu Allez
Mar 16, 2017·Inflammatory Bowel Diseases·Sebastian Zundler, Markus F Neurath
Aug 2, 2018·The Cochrane Database of Systematic Reviews·Seana Ml NelsonJohn K MacDonald
Nov 18, 2018·Expert Opinion on Therapeutic Patents·Hao LiJi-Fu Wei
May 23, 2018·Inflammatory Bowel Diseases·Amy HemperlyNiels Vande Casteele
Feb 1, 2017·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·Z A GoncharovaV A Megeryan
Feb 22, 2017·Inflammatory Bowel Diseases·Sebastian ZundlerMarkus F Neurath
Apr 5, 2017·World Journal of Gastroenterology : WJG·Michael K ZhengGary C Chen
Apr 4, 2018·The American Journal of Gastroenterology·Gary R LichtensteinBruce E Sands
Feb 19, 2019·Frontiers in Pharmacology·Charlotte LichnogSebastian Zundler
Jul 14, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Pavine L C LefevreNiels Vande Casteele
May 4, 2021·Frontiers in Pharmacology·Badr Al-BawardyDeborah D Proctor

❮ Previous
Next ❯

Software Mentioned

Comprehensive Meta - Analysis
Google Scholar

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.